Assessment of compliance with anaemia treatment on patients that received metoxipolietilenglicol epoetin beta compared with conventional erythropoietin, and its relation with clinical outcomes on HMO
- At: 2009 FIP Congress in Istanbul (Turkey)
- Type: Poster
- By: OLMOS, Virginia (Asociacion Española, Montevideo, Uruguay)
- Co-author(s): Pignataro, Jorge (Hoffman La Roche, MONTEVIDEO, Uruguay)
Olmos, Ismael (Asociacion Española, MONTEVIDEO, Uruguay)
Daners, Martin (Asociacion Española, MONTEVIDEO, Uruguay)
Objective To evaluate compliance to renal anaemia treatment with methoxy-polyethyleneglycol-epo beta on patients with renal impairment currently treated with a conventional erythropoiesis stimulating agent (ESA). The cost implications of the treatment and their impact on the global budget of a private health institution in Uruguay were also.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.